98%
921
2 minutes
20
Background: This study investigated the association between the Mini-Mental State Examination-2 (MMSE-2) and the Korean version of the Mini-Mental State Examination (K-MMSE) scores with global cortical gray matter volume changes in healthy older adults, patients with mild cognitive impairment (MCI), and Alzheimer's Disease (AD) in Korea. Using voxel-based morphometry analysis of structural magnetic resonance imaging (MRI), we explored how these correlations evolve with the progression of cognitive impairment. Additionally, we identified brain regions linked to the newly added components of MMSE-2, such as story memory and processing speed.
Methods: A total of 22 patients with MCI, 11 patients with AD, and 10 healthy controls were enrolled based on a comprehensive neuropsychological assessment. All participants underwent brain MRI within six months of completing both the MMSE-2 and K-MMSE. MRI data were acquired using T1-weighted three-dimensional spoiled gradient echo sequences on a Philips Intera Achieva 3.0T scanner. Image preprocessing and analysis were conducted using MATLAB and Statistical Parametric Mapping (SPM5). Multiple regression analysis was performed to compare gray matter volumes across groups, with adjustments for age and education. Statistical significance was set at = 0.005 with a voxel threshold of 100, and brain atrophy regions were identified using Talairach Client 2.4.2.
Results: MMSE-2 scores demonstrated stronger and more extensive correlations with gray matter volume than K-MMSE scores. Specifically, MMSE-2: Brief Version was associated with the left fusiform gyrus and left inferior temporal gyri, while MMSE-2: Standard Version extended its correlations to include regions such as the hippocampus. Notably, MMSE-2: Expanded Version (EV) exhibited the most robust and widespread associations, involving frontal, temporal, and occipital regions. In contrast, K-MMSE scores showed more limited regional correlations, primarily focusing on the fusiform gyrus, hippocampus, and cuneus.
Conclusion: The MMSE-2 demonstrated broader and stronger associations with cortical gray matter volume compared to the K-MMSE. In particular, MMSE-2:EV emerged as a more effective cognitive screening tool in clinical settings due to its widespread correlations across key brain regions, including the frontal lobe-a region inadequately assessed by the K-MMSE. These findings highlight the enhanced sensitivity of MMSE-2 in detecting structural brain changes associated with cognitive decline.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12303662 | PMC |
http://dx.doi.org/10.3346/jkms.2025.40.e167 | DOI Listing |
J Prev Alzheimers Dis
September 2025
Stanford Neuroscience Health Center, Stanford University, Palo Alto CA USA.
Background: AR1001 is a phosphodiesterase-5 inhibitor that produces improved cognitive performance and reduces amyloid-β and phosphorylated tau burdens in preclinical models of Alzheimer's disease (AD).
Objectives: To evaluate the safety and efficacy of AR1001 in participants with mild-to-moderate Alzheimer's disease (AD).
Design: Randomized, double-blind, placebo-controlled phase 2 trial conducted at 21 sites in the United States.
Clin Nutr ESPEN
September 2025
Department of Nutrition, Graduate School of Human Life and Ecology, Osaka Metropolitan University, 2-1-132, Osaka-shi, Osaka 536-8525, JAPAN; Department of Endocrinology and Metabolism, Hospital, National Center for Geriatrics and Gerontology, 7-430 Moriokachō, Obu, Aichi, 474-0038, Japan. Electron
Background & Aims: Vitamin D deficiency has been associated with cognitive decline and Alzheimer's disease (AD); however, findings remain inconsistent. Assessing vitamin D status based solely on total 25-hydroxyvitamin D [25(OH)D] may be insufficient, and other metabolites, such as 24,25-dihydroxyvitamin D [24,25(OH)D] and 3-epimer-25-hydroxyvitamin D [3-epi-25(OH)D], may provide additional insights. This study aimed to examine the association between serum vitamin D metabolite concentrations and cognitive function in older adults.
View Article and Find Full Text PDFGeroscience
September 2025
Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
Introduction: Cancer is associated with accelerated aging, including changes in muscle composition and cognition. However, the relationship between myosteatosis and cognitive function has not been investigated in older cancer survivors. This study evaluated the association between myosteatosis and cognitive function in this population.
View Article and Find Full Text PDFWien Klin Wochenschr
September 2025
Department of Neurology, Medical University of Vienna, Vienna, Austria.
Background: Disease-modifying therapies with amyloid-antibodies will soon be available for patients with early Alzheimer's disease, which necessitates diagnostic and therapeutic resources in hospital and outpatient settings.
Methods: The Austrian Alzheimer Society developed an online questionnaire to survey Austrian hospital-based departments of neurology and psychiatry regarding resources for amyloid-antibody therapies.
Results: Between May and October 2023, 30 out of 41 neurology (73%) and 12 out of 33 psychiatry departments (36%) responded.
Front Neurosci
August 2025
Department of Radiology Imaging Center, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Objective: This study aims to investigate the effects of Type 2 Diabetes Mellitus (T2DM) on brain function in patients with Obstructive Sleep Apnea (OSA) using Regional Homogeneity (ReHo) combined with seed-based Functional Connectivity (FC) methods.
Materials And Methods: 46 OSA patients, 38 OSA with T2DM patients, and 34 healthy controls (HC) were prospectively recruited. Clinical data were collected from all participants, and neuropsychological testing was performed using the Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE), and Epworth Sleepiness Scale (ESS).